Inovio Pharmaceuticals, Inc. (INO)
1.02
-0.02
(-1.92%)
USD |
NASDAQ |
Oct 16, 11:59
Inovio Pharmaceuticals SG&A Expense (TTM) : 30.77M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 30.77M |
| March 31, 2026 | 31.54M |
| December 31, 2025 | 32.68M |
| September 30, 2025 | 33.07M |
| June 30, 2025 | 33.80M |
| March 31, 2025 | 35.45M |
| December 31, 2024 | 36.99M |
| September 30, 2024 | 39.64M |
| June 30, 2024 | 40.95M |
| March 31, 2024 | 44.26M |
| December 31, 2023 | 47.58M |
| September 30, 2023 | 51.29M |
| June 30, 2023 | 53.19M |
| March 31, 2023 | 88.12M |
| December 31, 2022 | 90.19M |
| September 30, 2022 | 90.28M |
| June 30, 2022 | 91.62M |
| March 31, 2022 | 55.82M |
| December 31, 2021 | 53.75M |
| September 30, 2021 | 48.32M |
| June 30, 2021 | 45.28M |
| March 31, 2021 | 43.68M |
| December 31, 2020 | 37.25M |
| September 30, 2020 | 37.33M |
| June 30, 2020 | 32.90M |
| Date | Value |
|---|---|
| March 31, 2020 | 27.68M |
| December 31, 2019 | 27.20M |
| September 30, 2019 | 24.14M |
| June 30, 2019 | 25.25M |
| March 31, 2019 | 26.59M |
| December 31, 2018 | 29.32M |
| September 30, 2018 | 31.71M |
| June 30, 2018 | 31.24M |
| March 31, 2018 | 30.22M |
| December 31, 2017 | 28.29M |
| September 30, 2017 | 27.22M |
| June 30, 2017 | 26.66M |
| March 31, 2017 | 26.29M |
| December 31, 2016 | 23.89M |
| September 30, 2016 | 21.79M |
| June 30, 2016 | 20.41M |
| March 31, 2016 | 19.33M |
| December 31, 2015 | 18.06M |
| September 30, 2015 | 17.43M |
| June 30, 2015 | 16.20M |
| March 31, 2015 | 15.83M |
| December 31, 2014 | 15.86M |
| September 30, 2014 | 15.97M |
| June 30, 2014 | 16.10M |
| March 31, 2014 | 14.80M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Nektar Therapeutics | 53.46M |
| Ironwood Pharmaceuticals, Inc. | 64.55M |
| Fortress Biotech, Inc. | 68.84M |
| Tonix Pharmaceuticals Holding Corp. | 125.96M |
| Kura Oncology, Inc. | 135.28M |